Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma
Author:
- 1 May 2005
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 15 (s1) , 18-22
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinomaInvestigational New Drugs, 2004
- Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancerGynecologic Oncology, 2003
- Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trialThe Lancet, 2002
- Randomized Controlled Trial of Single-Agent Paclitaxel Versus Cyclophosphamide, Doxorubicin, and Cisplatin in Patients With Recurrent Ovarian Cancer Who Responded to First-Line Platinum-Based RegimensJournal of Clinical Oncology, 2002
- Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cellsBiochemical Pharmacology, 2000
- Second-Line Treatment of Ovarian CancerThe Oncologist, 2000
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI: Journal of the National Cancer Institute, 1994
- Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.Journal of Clinical Investigation, 1994
- Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cellsAnti-Cancer Drugs, 1991